Who
Andrew Cittadine
Chief Operating Officer
Company insider
Files Form 4 as: Chief Operating Officer, Monopar Therapeutics.
In numbers
- Trades disclosed
- 86
- Buys
- 12
- Sells
- 0
- Bought
- $150K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 1 Jun 2021
- Last trade
- 30 Sep 2026
- Last filed
- 2 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Sep 2026filed 2 Oct 2026 | MNPR Monopar TherapeuticsBiotechnology | SEC FORM 4 Code M | —4,384 | filing |
| 30 Sep 2026filed 2 Oct 2026 | MNPR Monopar TherapeuticsBiotechnology | SEC FORM 4 Code F | $155K1,944 at $79.67 | filing |
| 30 Sep 2026filed 2 Oct 2026 | MNPR Monopar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,384 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | MNPR Monopar TherapeuticsBiotechnology | SEC FORM 4 Code M | —5,254 | filing |
| 30 Jun 2026filed 2 Jul 2026 | MNPR Monopar TherapeuticsBiotechnology | SEC FORM 4 Code F | $214K2,309 at $92.59 | filing |
| 30 Jun 2026filed 2 Jul 2026 | MNPR Monopar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,254 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | MNPR Monopar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,254 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | MNPR Monopar TherapeuticsBiotechnology | SEC FORM 4 Code M | —5,254 | filing |
| 30 Jun 2026filed 2 Jul 2026 | MNPR Monopar TherapeuticsBiotechnology | SEC FORM 4 Code F | $214K2,309 at $92.59 | filing |
| 31 Mar 2026filed 2 Apr 2026 | MNPR Monopar TherapeuticsBiotechnology | SEC FORM 4 Code M | —3,514 | filing |
| 31 Mar 2026filed 2 Apr 2026 | MNPR Monopar TherapeuticsBiotechnology | SEC FORM 4 Code F | $86K1,571 at $54.79 | filing |
| 31 Mar 2026filed 2 Apr 2026 | MNPR Monopar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,514 at $0.00 | filing |
| 31 Mar 2026filed 2 Apr 2026 | MNPR Monopar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,514 at $0.00 | filing |
| 31 Mar 2026filed 2 Apr 2026 | MNPR Monopar TherapeuticsBiotechnology | SEC FORM 4 Code M | —3,514 | filing |
| 31 Mar 2026filed 2 Apr 2026 | MNPR Monopar TherapeuticsBiotechnology | SEC FORM 4 Code F | $86K1,571 at $54.79 | filing |
| 31 Dec 2025filed 5 Jan 2026 | MNPR Monopar TherapeuticsBiotechnology | SEC FORM 4 Code M | —4,326 | filing |
| 31 Dec 2025filed 5 Jan 2026 | MNPR Monopar TherapeuticsBiotechnology | SEC FORM 4 Code F | $123K1,889 at $65.30 | filing |
| 31 Dec 2025filed 5 Jan 2026 | MNPR Monopar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,326 at $0.00 | filing |
| 31 Dec 2025filed 5 Jan 2026 | MNPR Monopar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,326 at $0.00 | filing |
| 31 Dec 2025filed 5 Jan 2026 | MNPR Monopar TherapeuticsBiotechnology | SEC FORM 4 Code M | —4,326 | filing |
News
No headline names them, or the companies they trade most, lately.